Sign up United Kingdom
Proactive Investors - Run By Investors For Investors

Faron Pharmaceuticals looks to Clevegen opportunity after Traumakine disappointment

Clevegen has shown no toxicologically relevant changes in any subject in dose escalation studies.
man on a ventilator
The drug was administered as a single dose at 3, 30 and 100 mg/kg in the three-week toxicity study

Faron Pharmaceuticals Ltd (LON:FARN) plans to file a clinical trial application for Clevegen after a study into the safety and efficacy of the cancer treatment.

Clevegen showed no toxicologically relevant changes in any subject in dose escalation studies. 

READ: Faron Pharmaceuticals to file clinical trial application for Clevegen after successful study

The drug was administered as a single dose at 3, 30 and 100 mg/kg in the three-week toxicity study.

The highest dose of 100 mg/kg was considered the no-observed-adverse-effect-level (NOAEL).

The pre-clinical study also showed Clevegen administration blocks Clever-1 on circulating monocytes, precursor cells to tumour-associated macrophages.

Clever-1 is an endothelial cell surface molecule involved in cancer growth and its spread.

Dr Markku Jalkanen, chief executive of Faron, says the results are an “encouraging” first step.

"We are very encouraged to find out about the good safety profile of our wholly-owned asset Clevegen and the high NOAEL concentration," Jalkanen said, adding: "We were also delighted to learn that Clevegen administration blocks Clever-1 on circulating monocytes, which are one group of our target cells in our MATINS Phase I/II clinical trial.

Our plan is now to file the MATINS clinical trial application (CTA) during Q3 2018 and, as previously announced, initiate this first Clevegen human trial in Q4 2018."

Traumakine disappointment

The move comes after a difficult first half for the company, which saw its stock take a major hit in May after its flagship Traumakine drug did not meet efficacy requirements following the initial read-out from its phase III INTEREST study.

Traumakine was used to treat acute respiratory distress syndrome (ARDS), a life-threatening ailment caused by an inflammation of the lungs that usually coincides with illnesses such as pneumonia or severe flu. 

The trial found that at 28 days the median number of ventilator-free days for patients on the drug was 10 days, only slightly higher than the 8.5 days for those taking a placebo with no medical benefit.

Meanwhile, the mortality rate after four weeks was 26.4% for those receiving the Faron treatment and 23% for the placebo group.

Faron's team is still trying to understand why Traumakine activity was variable in the INTEREST trial compared to previous studies and why the mortality was so low in the group receiving the dummy placebo drug.

"This analysis will continue and we will keep our shareholders and the market informed with progress in due course," Jalkanen said.

View full FARN profile View Profile

Faron Pharmaceuticals Ltd Timeline

Newswire
September 12 2018

Related Articles

Zelda's Stewart Washer at Proactive's CEO Sessions
November 17 2017
Stewart Washer at Proactive's CEO Sessions this week.
Callitas CEO James Thompson
July 20 2018
CannaStrips will generate near-term revenue, while the company’s blue-sky pharmaceutical assets and orphan drug are solid, long-term plays
Picture of growing facility
May 07 2018
Establishing a vertically integrated business model provides THC with the ability to optimise efficiencies in the manufacturing process.

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

© Proactive Investors 2018

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use